TY - JOUR
T1 - Development of a novel anti-HER2 monoclonal antibody H2Mab-181 for gastric cancer
AU - Takei, Junko
AU - Asano, Teizo
AU - Tanaka, Tomohiro
AU - Sano, Masato
AU - Hosono, Hideki
AU - Nanamiya, Ren
AU - Tateyama, Nami
AU - Saito, Masaki
AU - Suzuki, Hiroyoshi
AU - Harada, Hiroyuki
AU - Kaneko, Mika K.
AU - Kato, Yukinari
N1 - Funding Information:
This research was supported, in part, by Japan Agency for Medical Research and Development (AMED) under grant numbers: JP21am0401013 (to Yukinari Kato) and JP21am0101078 (to Yukinari Kato) and by the Japan Society for the Promotion of Science ( JSPS) Grants-in-Aid for Scientific Research (KAKENHI) grant numbers 21K15523 (to Teizo Asano), 21K07168 (to Mika K. Kaneko), 20K16322 (to Masato Sano), and 19K07705 (to Yukinari Kato).
Publisher Copyright:
© Copyright 2021, Mary Ann Liebert, Inc., publishers 2021.
PY - 2021/8/1
Y1 - 2021/8/1
N2 - Human epidermal growth factor receptor 2 (HER2) is a type I transmembrane 185 kDa protein. HER2 is expressed in a variety of normal tissue types and cancer cells. HER2 is associated with cell proliferation, differentiation, and migration. The overexpression of HER2 has been observed in a number of cancers, including breast and gastric cancers. Gastric cancer is one of the most common cancers worldwide, with an annual case rate of ∼1 million people diagnosed with the disease. Trastuzumab is a humanized anti-HER2 monoclonal antibody (mAb) that has been utilized in gastric cancer therapy. In this study, we have developed a novel anti-HER2 mAb, H2Mab-181 (IgG1, kappa), through the immunization of mice with a purified recombinant extracellular domain of HER2. H2Mab-181 can specifically and sensitively detect HER2 in both flow cytometry and Western blot applications in gastric cancer cell lines and can also be utilized in immunohistochemical analyses of gastric cancer tissues. Together, H2Mab-181 could be useful for the diagnosis and therapy in gastric cancers.
AB - Human epidermal growth factor receptor 2 (HER2) is a type I transmembrane 185 kDa protein. HER2 is expressed in a variety of normal tissue types and cancer cells. HER2 is associated with cell proliferation, differentiation, and migration. The overexpression of HER2 has been observed in a number of cancers, including breast and gastric cancers. Gastric cancer is one of the most common cancers worldwide, with an annual case rate of ∼1 million people diagnosed with the disease. Trastuzumab is a humanized anti-HER2 monoclonal antibody (mAb) that has been utilized in gastric cancer therapy. In this study, we have developed a novel anti-HER2 mAb, H2Mab-181 (IgG1, kappa), through the immunization of mice with a purified recombinant extracellular domain of HER2. H2Mab-181 can specifically and sensitively detect HER2 in both flow cytometry and Western blot applications in gastric cancer cell lines and can also be utilized in immunohistochemical analyses of gastric cancer tissues. Together, H2Mab-181 could be useful for the diagnosis and therapy in gastric cancers.
KW - HER2
KW - gastric cancer
KW - monoclonal antibody
UR - http://www.scopus.com/inward/record.url?scp=85113783618&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85113783618&partnerID=8YFLogxK
U2 - 10.1089/mab.2021.0021
DO - 10.1089/mab.2021.0021
M3 - Article
C2 - 34424764
AN - SCOPUS:85113783618
VL - 40
SP - 168
EP - 176
JO - Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
JF - Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
SN - 2167-9436
IS - 4
ER -
